Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy
The Motley Fool
by newsfeedback@fool.com (Jonathan Ponciano)February 23, 2026
AI-Generated Deep Dive Summary
Kodiak Sciences (NASDAQ: KOD) experienced a nearly fivefold surge in its stock price, rising 480%, following a significant investment by Baker Bros. Advisors LP. The hedge fund disclosed the purchase of 2,608,696 shares valued at an estimated $53.42 million based on quarterly average pricing. This move, revealed through an SEC filing on February 17, 2026, marked a substantial increase in Baker Bros.' stake in Kodiak during the fourth quarter of 2025. The transaction not only boosted their holdings but also contributed to a $273.57 million rise in the value of their Kodiak Sciences portfolio by the end of the quarter.
Kodiak Sciences specializes in developing therapeutic solutions for retinal diseases, a field with high unmet medical needs and significant growth potential. The company’s pipeline includes promising treatments targeting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy, which affect millions globally. Baker Bros.' investment reflects confidence in Kodiak's ability to advance its drug candidates through clinical trials and bring them to market.
This stock volatility highlights the speculative nature of biotech investments,
Verticals
financeinvesting
Originally published on The Motley Fool on 2/23/2026